Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5805909 | 0.84 | NFE2L2 (0.42) | NFE2L2KDM4EPDGFRBPDGFRACA12 | |
| SCHEMBL5747161 | 0.80 | PTGDR2 (0.38) | USP2MAOBFFAR1FFAR4 | |
| SCHEMBL551293 | 0.80 | AR (0.53) | KDM4EUSP2ALDH1A1AR | |
| SCHEMBL5127252 | 0.80 | KDM4E (0.39) | NFE2L2KDM4EPDGFRBPDGFRACA12 | |
| SCHEMBL3434561 | 0.78 | CA12 (0.56) | NFE2L2CA12CA1CA2CA7 | |
| SCHEMBL14661785 | 0.76 | PYCR1 (0.47) | KDM4EUSP2ALDH1A1ARTSHR | |
| SCHEMBL22031537 | 0.76 | KDM4E (0.35) | KDM4ECA12CA1CA2CA4 | |
| SCHEMBL14661781 | 0.76 | ALDH1A1 (0.56) | KDM4EUSP2ALDH1A1TSHRMAPT | |
| SCHEMBL15611480 | 0.76 | TRPV4 (0.46) | KDM4EUSP2ALDH1A1MEN1MAPT | |
| SCHEMBL1053468 | 0.75 | P2RX3 (0.43) | KDM4ECA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709301-B | Pyrazole derivative or pharmacologically acceptable salt thereof | 橘生药品工业株式会社 | 2021-06-22 | — | — | CN | disclosed |
| US-10287251-B2 | Pyrazole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| US-20180170879-A1 | PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180170879-A1 | PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| EP-3315492-A1 | PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-6482478-B1 | Fluorinated derivatives of phenanthrene and the utilization thereof in liquid crystal mixtures | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2002-11-19 | — | — | US | disclosed |
| EP-1028935-A1 | FLUORINATED DERIVATIVES OF PHENANTHRENE AND THE UTILIZATION THEREOF IN LIQUID CRYSTAL MIXTURES | Aventis Research & Technologies GmbH & Co KG (DE) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024385-A1 | FLUORINATED DERIVATIVES OF PHENANTHRENE AND THE UTILIZATION THEREOF IN LIQUID CRYSTAL MIXTURES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287251-B2 | Pyrazole derivative or pharmaceutically acceptable salt thereof | TRPM8, HCN3, HCN4 | NFE2L2 4457/4885KDM4E 2007/4885PDGFRB 2937/4885 |
| US-20180170879-A1 | PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TRPM8, HCN3, HCN4 | NFE2L2 4588/4885KDM4E 1897/4885PDGFRB 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.